The role of receptor binding in the toxicity, immunogenicity, and adjuvanticity of the heat-labile enterotoxin of Escherichia coli (LT) was examined by comparing native LT and LT(G33D), a B-subunit receptor binding mutant, with respect to the ability to bind to galactose and to GM1, toxicity on mouse Y-1 adrenal tumor cells, the ability to stimulate adenylate cyclase in Caco-2 cells, enterotoxicity in the patent mouse model, and oral immunogenicity and adjuvanticity. In contrast to native LT, LT(G33D) was unable to bind to the galactosyl moiety of Sepharose 4B or GM1 but did retain the lectin-like ability to bind to immobilized galactose on 6% agarose beads. LT(G33D) had no enterotoxicity in the patent mouse model but exhibited residual toxicity on mouse Y-1 adrenal tumor cells and had an ability equivalent to that of native LT to stimulate adenylate cyclase in Caco-2 cells (5,000 versus 6,900 pmol per mg of protein). In addition, LT(G33D) was unable to serve as an effective oral adjuvant for induction of immunoglobulin G or A directed against a coadministered antigen. Furthermore, LT(G33D) elicited negligible serum and mucosal antibody responses against itself. These data indicate that the toxicity, immunogenicity, and oral adjuvanticity of LT are dependent upon binding of the B subunit to ganglioside GM1.
Enterotoxigenic Escherichia coli causes diarrheal disease by production of one or more enterotoxins. One of these is a high-molecular-weight heat-labile toxin (LT) which is immunologically and physicochemically related to cholera toxin (CT) (10, 12) . Both LT and CT are synthesized as multisubunit toxins with A and B components. Upon thiol reduction, the A component dissociates into two smaller polypeptide chains. One of these, the A 1 piece, catalyzes the ADP-ribosylation of the stimulatory GTP-binding protein in the adenylate cyclase enzyme complex on the basolateral surface of the epithelial cell, resulting in increased intracellular levels of cyclic AMP (cAMP). The resulting increase in cAMP causes secretion of water and electrolytes into the small intestine through interaction with two cAMP-sensitive ion transport mechanisms involving (i) NaCl cotransport across the brush border of villous epithelial cells and (ii) electrogenic Na-dependent C1 secretion by crypt cells (23) . The B subunit binds to the host cell membrane receptor (ganglioside GM1) and facilitates the translocation of the A subunit through the cell membrane. A number of recent studies have indicated that the translocation of the A subunit occurs from an endosomal compartment after endocytosis (7, 30, 31) . Although different conclusions have been drawn regarding the roles of potential endoplasmic retention sequences (RDEL, RNEL, and KDEL) and retrograde transport of the A subunit through the Golgi apparatus-endoplasmic reticulum complex in the targeting of LT and CT to the basolateral surface, it is clear from these studies that toxin translocation from the apical to the basolateral surface of the epithelial cell requires endocytosis and processing in one or more intracellular compartments.
Targeting of LT and CT to this pathway begins with binding of the toxin to the epithelial cell surface. A number of chemical and genetic mutational studies which, when combined with X-ray crystallography, give a clear picture of the events associated with the interaction of the B subunit with the GM1 pentasaccharide have been performed (28, 34, 40, (42) (43) (44) 48) ; in addition, site-directed mutagenesis of LT-B and CT-B has revealed a number of amino acids that are more or less critical if this binding event is to occur (28, 40, 48) . Jobling and Holmes (28) examined six different residues in CT-B and demonstrated that substitution of negatively charged or large hydrophobic residues for G33 or negatively or positively charged residues for W88 caused decreased binding to GM1. Moreover, they established the role of receptor binding in adrenalcell toxicity for CT and confirmed the role of G33 in GM1 binding for CT that had been established by Tsuji et al. (48) for LT-B. While Tsuji et al. (48) did identify G33 as a critical residue for GM1 binding by LT-B, they did not address the role of receptor binding in the toxicity of LT.
LT-B and CT-B are two highly immunogenic proteins and have been widely studied as oral immunogens and as immunologic carriers of other antigens for mucosal immunization (2, 5, 13-15, 19-21, 26, 32, 47) . The importance of receptor binding for the immunogenicity of LT-B was recently examined by Nashar et al. (35) . In those studies, the immunogenicity of a G33D receptor binding mutant of LT-B, equivalent to the CT-B mutant of Jobling and Holmes (28) , was shown to be greatly reduced following subcutaneous immunization compared with that of native LT-B and completely eliminated following oral immunization. Moreover, when lymphocytes from mesenteric lymph nodes were examined, immunization with native LT-B, in contrast to immunization with the G33D mutant, was found to cause an increase in the proportion of B cells, increased activation of B cells and CD4 ϩ T cells, and complete depletion of CD8 ϩ T cells. That study makes it clear that the potent mucosal immunogenicity of LT-B is dependent upon efficient receptor binding. The study did not, however, address the role of receptor binding in the toxicity or immunogenicity of the LT holotoxin. In addition to their exceptional immunogenicities, both LT and CT have significant immunoregulatory potential, not only as means of preventing the in-duction of tolerance but also as adjuvants for mucosally administered antigens (see reference 17 for a recent review). None of the studies conducted to date has addressed the role of receptor binding in the adjuvanticity of these molecules.
Although LT and CT have many features in common, they are clearly distinct molecules with biochemical and immunologic differences which make them unique (17) . In addition, LT has an unusual affinity for carbohydrate-containing matrices (10, 12) . LT binds not only to agarose in columns used for purification but also, more importantly, to other biological molecules containing galactose, including glycoproteins and lipopolysaccharides. This lectin-like binding property of LT results in a broader range of receptors on mammalian cells for LT than for CT, which binds only to GM1 (1, 12, 25) . Taking into account this difference in binding properties between LT and CT and the findings of Nashar et al. (35) regarding the importance of receptor binding for the immunogenicity of LT-B, in the present study we examined the role of GM1 binding in the toxicity, immunogenicity, and adjuvanticity of the LT holotoxin.
MATERIALS AND METHODS
Bacterial strains and plasmids. E. coli JM83(pJC217) F Ϫ 80⌬lacZ ⌬M15 ⌬(lac-proAB) ara rpsL is a K-12 derivative transformed with pJC217, a 3.5-kb pUC18-based plasmid which contains the gene for production of LT-B (9). E. coli BMH 71-18 mutS thi supE ⌬(lac-proAB) (mutS::Tn10) (FЈ proA ϩ B ϩ lacI q Z⌬M15) (Promega, Madison, Wis.) is a highly transformable mismatch repair-negative strain used in site-directed mutagenesis to obtain high mutation efficiencies. Plasmid pBD94 is a pUC18 derivative containing the LT-A and the LT-B genes cloned in the same reading frame and under control of the lac promoter (16) . Plasmid pJG94 (this study) is isogenic to pBD94, except for a single point mutation within the B subunit.
Media. Transformants of E. coli JM83 were screened on Luria-Bertani agar plates containing 100 g of ampicillin (Sigma Chemical Co., St. Louis, Mo.) per ml. Transformed E. coli BMH 71-18 was grown in Luria-Bertani liquid medium supplemented with 100 g of ampicillin per ml.
DNA sequencing. DNA sequencing was performed on a 6% acrylamide-bisacrylamide gel with a Sequi-Gen nucleic acid sequencing cell (Bio-Rad, Richmond, Calif.) and a Sequenase version 2.0 sequencing kit (United States Biochemical, Cleveland, Ohio); this procedure is a variation of the dideoxynucleotide chain termination method (41) . The single nucleotide mutation was confirmed by sequencing with a specific 20-mer (5Ј-CTTCGACCTGAAATGTTGCG-3Ј) designed to anneal 36 nucleotides upstream of the mutation site.
Site-directed mutagenesis. A mutagenic oligonucleotide (5Ј-TTCTCTTTTGT CTGCCATGGATTCCGTATA-3Ј) was designed to incorporate a single nucleotide substitution within the B subunit which would replace the wild-type glycine residue (GGC) with an aspartate (GAC) at amino acid 33 from the N terminus of the B subunit. This mutagenic oligonucleotide was also designed to create a unique NcoI (Gibco BRL) restriction site and delete a unique ClaI (Gibco BRL) restriction site in the translated region of the B subunit without altering the coding sequence.
Purification of native LT and LT(G33D). E. coli JM83(pBD94) and E. coli JM83(pJG94) were cultured as described above, and LT and LT(G33D) were purified by agarose affinity chromatography (10) . The native and mutant heatlabile enterotoxins were purified from cultures grown overnight in a 10-liter fermentor containing Trypticase soy broth (BBL, Cockeysville, Md.) supplemented with 100 g of ampicillin per ml. The cells were harvested by centrifugation, resuspended in TEAN (0.2 M NaCl, 0.05 M Tris, 0.001 M EDTA, 0.003 M NaN 3 [pH 7.5]), and lysed with a French press, and the lysate was clarified by centrifugation and extensively dialyzed against TEAN. The clarified lysate was subjected to high-speed centrifugation prior to chromatography on Sepharose 4B (Pharmacia) or immobilized D-galactose (Pierce, Rockford, Ill.) columns. Native LT and LT(G33D) were eluted with 0.3 M galactose (Acros Organics, Fisher) in TEAN. Holotoxin (AB5 fractions) was purified and separated from free Bsubunit pentamer (B5) by size exclusion chromatography with a BioGel P100 column (Bio-Rad, Hercules, Calif.). LT-B used in this study had been prepared in this laboratory from E. coli JM83(pJC217) as previously described (10) .
Agarose gel electrophoresis and SDS-PAGE. Agarose gel electrophoresis was performed with 0.04 M Tris-0.2 M sodium acetate-0.0002M EDTA (pH 7.8) and 1% agarose gels (Gibco BRL). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed by the technique of Laemmli (29) . Each well contained 10 g of protein, and gels were stained with 0.25% Coomassie brilliant blue in 40% methanol and 7% acetic acid. Where indicated, native LT and LT(G33D) were activated with trypsin (Sigma) at a concentration of 1 ng per g of protein for 45 min at 37°C. Prior to SDS-PAGE analysis, the samples were mixed with sample buffer containing SDS and dithiothreitol and heated to 100°C for 3 min. To visualize undenatured proteins, samples were not heated.
Y-1 adrenal tumor cell assay. Mouse Y-1 adrenal tumor cells (ATCC CCL-79) were seeded in 96-well round-bottom plates at a concentration of 2 ϫ 10 4 cells per well (39) . One microgram each of native LT, LT-B, and LT(G33D) was activated for 45 min at 37°C in the presence of 1.0 ng of trypsin (Sigma) in a final reaction volume of 100 l and then serially diluted prior to incubation with Y-1 adrenal tumor cells at 37°C in 5% CO 2 overnight. The following day, the cells were examined by light microscopy for typical cell rounding. Titers were defined as the minimum concentrations of toxin required to give more than 50% cell rounding.
Determination of intracellular levels of cAMP. Caco-2 cells were obtained from the American Type Culture Collection (ATCC HTB 37) and were maintained in Eagle's minimum essential medium (EMEM) supplemented with 1% nonessential amino acids and 15% fetal bovine serum (FBS) (Gibco BRL). Intracellular accumulation of cAMP was determined as described previously (24) . Cells were seeded in six-well cluster plates (Corning Costar, Cambridge, Mass.) and grown to near confluency. Prior to addition of LT, LT(G33D), or LT-B, cells were incubated in EMEM containing 1% FBS and 1 mM 3-isobutyl-1-methylxanthine (IBMX) (Sigma) for 30 min at 37°C in 5% CO 2 . One microgram of each toxin was treated with 1 ng of trypsin, incubated at 37°C for an hour, and resuspended in 100 l of EMEM containing 1% FBS and 1 mM IBMX. Trypsin-activated LT, LT(G33D), or LT-B was added to each well and incubated for various periods. At 1, 2, 3, and 4 h after toxin addition, cells were washed twice with cold phosphate-buffered saline (PBS). Intracellular cAMP was extracted by adding 1 ml of 0.1 N HCl to each well and incubating the wells at room temperature for 15 min. Each cell lysate was neutralized with NaOH prior to cAMP and protein quantitation. cAMP was measured with Amersham's cAMP 3 H assay system (Amersham Life Science, Inc., Arlington Heights, Ill.). Protein content was determined by a modification of the Bradford assay (3).
Adjuvanticity. The procedures for determination of adjuvanticity were the same as those described previously (11) . Briefly, groups of BALB/c mice were immunized orally with ovalbumin (OVA) or OVA in combination with equimolar amounts of LT, LT(G33D), or LT-B. Animals were inoculated intragastrically with a blunt-tipped feeding needle (Popper & Sons, Inc., New Hyde Park, N.Y.). Oral inoculations consisted of 0.5 ml of TEAN containing 5 mg of OVA and 17 g of LT-B. Following three weekly oral inoculations, animals were given boosters intraperitoneally (i.p.) with 1 g of OVA in 20% Maalox (William H. Rorer, Inc., Fort Washington, Pa.). One week after the i.p. inoculation, animals were sacrificed and assayed by enzyme-linked immunosorbent assay (ELISA) for serum immunoglobulin G (IgG) and fecal IgA antibodies directed against OVA and LT. Blood was collected by cardiac puncture, and serum samples were separated in Microtainer serum separator tubes (Becton Dickinson, Franklin Lakes, N.J.) and stored at Ϫ20°C until assayed. Fecal samples collected overnight prior to euthanasia were used to determine the presence of specific fecal antibodies. Fresh fecal pellets were lyophilized, resuspended in PBS-0.5% sodium azide (15 pellets per 800 l), vortexed, clarified by centrifugation, and stored at Ϫ20°C until assayed.
Immunogenicity. To determine the immunogenicities of the different preparations, groups of BALB/c mice were i.p. inoculated with 0.2 ml of TEAN containing equimolar amounts of the toxins [25 g of LT, 25 g of LT(G33D), or 17 g of LT-B]. On day 12 postinoculation, animals were bled prior to euthanasia, and the serum samples were processed and stored as described below for quantitation of serum anti-LT IgG by ELISA.
ELISA. To determine the ability of LT(G33D) to bind to gangliosides, microtiter plates were coated with 1.5 g of Sigma mixed gangliosides (type III) in coating buffer per well or directly with LT, LT(G33D), or LT-B, each serially diluted in coating buffer. After being washed with PBS-0.05% Tween, ganglioside-coated plates were incubated with serial dilutions of LT, LT(G33D), or LT-B. Both ganglioside-coated and toxin-coated plates were further incubated with affinity-purified goat antiserum against LT followed by rabbit antiserum against goat IgG conjugated to alkaline phosphatase.
The levels of serum IgG and mucosal IgA antibodies directed against OVA and LT were determined by ELISA. Reagents and antisera for the ELISA were obtained from Sigma unless indicated otherwise. Samples for ELISA were diluted in twofold serial dilutions in PBS-0.05% Tween 20. For anti-LT determinations, microtiter plates were precoated with 1.5 g of mixed gangliosides (type III) per well and then with 1 g of purified LT per well. Anti-OVA was quantitated on microtiter plates precoated with 10 g of OVA per well. Anti-LT and anti-OVA IgG levels were determined with rabbit antiserum against mouse IgG conjugated to alkaline phosphatase. The presence of IgA specific for LT or for OVA was detected with goat antiserum against mouse IgA (␣ chain specific) conjugated to alkaline phosphatase. Reactions were stopped with 3 N NaOH, and the optical densities at 405 nm were determined with a Microplate reader (Bio-Tek, Winooski, Vt.). Results are expressed as titers, defined as the highest dilutions of serum or fecal extract that produced an optical density at 405 nm of 0.2.
Patent mouse gut assay. In vivo toxicity was determined by a patent mouse gut assay, determined at 3 and 8 h after administration of LT, LT(G33D), or LT-B. Three female BALB/c mice per group were inoculated intragastrically with 0.5 ml of PBS alone or in conjunction with one of the following: 1, 5, 25, or 125 g of native LT; 25 or 125 g of LT(G33D); or 25 or 125 g of LT-B. The mice remained in their cages without food but with water ad libitum for 3 or 8 h, after which they were sacrificed by CO 2 inhalation. The entire intestine from duodenum to anus was carefully removed to retain any accumulated fluid, and residual mesentery was removed prior to weighing. The carcass was weighed separately and a gut/carcass ratio was calculated for each animal. Values represent the mean gut/carcass ratio for each group. The patent mouse assay is a modification of the sealed adult-mouse assay of Richardson et al. (38) .
Statistical analysis. The standard errors of the means were calculated for all data, and means of variously immunized groups were compared by the Student t test. Statistical significance was considered to be a P value of Յ0.05.
RESULTS

Construction of LT(G33D).
To test the importance of receptor binding for the toxicity, immunogenicity, and adjuvanticity of LT, we constructed a B-subunit G33D mutant of LT and compared this molecule to native LT and LT-B. An aspartate residue was substituted by site-directed mutagenesis for the glycine at amino acid 33 (sequences were numbered from the amino terminus of the B subunit). Substituting aspartate for glycine at residue 33 the B subunit has been shown to abate GM1 binding by both CT-B and LT-B (28, 48) .
Site-directed mutagenesis was accomplished by constructing a mutagenic oligonucleotide incorporating a single nucleotide substitution within the B subunit, thereby converting the wildtype glycine 33 residue (GGC) to aspartate (GAC), and by a second (silent) change in the same oligonucleotide to convert an adjacent ClaI site to an NcoI site to facilitate screening. The mutagenic oligonucleotide was first annealed to singlestranded pBD94, and an in vitro synthesis reaction was performed as previously described (16) . Plasmid pBD94 is a pUC18 derivative containing the genes coding for both LT-A and LT-B in a polycistronic operon under the control of the lac promoter. Recombinant plasmids were then transformed into E. coli BMH 71-18 to allow strand segregation and amplification. Upon recovery, the plasmids were transformed into E. coli JM83, and individual colonies were screened for the desired mutation by restriction analysis with ClaI and NcoI. Clones sensitive to digestion with NcoI were screened for production of non-receptor-binding mutant LT by GM1 and non-GM1 ELISA and for the targeted nucleotide substitution by DNA sequencing. One such recombinant plasmid containing the single nucleotide substitution was identified and designated pJG94.
Characterization of LT(G33D). Mutant LT containing the aspartate 33 substitution in the B subunit was designated LT(G33D) and was purified from JM83(pJG94) by agarose affinity chromatography. As mentioned above, LT has an unusual affinity for carbohydrate-containing matrices and can be purified by affinity chromatography with galactose elution from agarose columns (10) . We have used a number of commercially prepared agarose gels for affinity purification of LT and routinely use Sepharose 4B for affinity purification of native LT and LT-B. As an alternative, we also use immobilized galactose on 6% beaded agarose. This matrix has a much higher binding capacity for LT-B than do other galactose matrices we have examined. When the LT(G33D) lysate was chromatographed on a Sepharose 4B column, analysis of the precolumn sample, column fractions, and galactose eluate by ELISA revealed that, in contrast to native LT and LT-B, LT(G33D) did not bind to the Sepharose 4B matrix. However, when the LT(G33D) lysate was applied to a 1.5-by 20-cm column of immobilized galactose, LT(G33D) bound to the galactose matrix and could be eluted with 0.3 M galactose (data not shown). These findings indicate that while the G33D mutation prevents binding of this mutant form of LT to GM1 and to the galactose component of Sepharose, it does not prevent LT(G33D) binding to immobilized galactose. LT(G33D) was then analyzed by SDS-PAGE. As shown in Fig. 1 , when the samples were boiled under reducing conditions, the 28-kDa A subunits of native LT (lane 4) and LT(G33D) (lane 6) remained intact and the B subunits migrated as 11,500-Da monomers. However, when the samples were not heated, the apparent molecular mass of the B subunit of LT(G33D) was 44 kDa (Fig. 1, lane 5) instead of the expected 56 kDa observed for native LT (lane 3). This observed differential migration of the oligomeric B subunits from native LT and LT(G33D) could have resulted from a difference in either charge or conformation resulting from the substitution of aspartate for glycine or from a reduced number of B subunits in the G33D mutant (i.e., tetramer versus pentamer).
In order to determine whether the mutant LT had the same molecular conformation as native LT, we mixed equal amounts of native LT and LT(G33D) and subjected this mixture to high-resolution gel filtration chromatography on a P-100 column. Both native LT and LT(G33D) are eluted within the included volume of this matrix, which can differentiate between an 84-kDa protein (A1B5) and a 72-kDa protein (A1B4). We reasoned that if LT(G33D) assembled as a B tetramer instead of a pentamer, two distinct peaks would be eluted when LT(G33D) was cochromatographed with native LT. Instead, a single peak was eluted from the column (data not shown). All of the fractions from this peak were pooled and examined by SDS-PAGE. As can be seen in Fig. 1, lane 1 , LT B5 and LT(G33D) B5 coeluted in this peak along with the A subunit. Electrophoresis of the boiled samples in the presence of a reducing agent revealed two distinct bands corresponding to LT-A and monomeric LT-B (Fig. 1, lane 2) . This observation indicates that both LT and LT(G33D) assemble as holotoxins and that the B moieties of both toxins assemble as pentamers. It is likely that the higher electrophoretic mobility observed for the B pentamer of LT(G33D) is due to the presence of the five negatively charged aspartate residues per Bsubunit pentamer.
In a recent study by Nashar et al. (35) , it was reported that the pentamer of a G33D mutant of LT-B exhibited a lower electrophoretic mobility than did pentameric native LT-B, while our results indicate a higher electrophoretic mobility for the G33D pentamer. One possible explanation for this difference is that the presence of the A subunit in our LT(G33D) mutant allows the holotoxin to adopt a quaternary structure that exposes a different set of amino acid residues on the exterior surface of the molecule and consequently causes dif-FIG. 1. Analytical discontinuous SDS-PAGE of thiol-reduced LT (lanes 3 and 4), LT(G33D) (lanes 5 and 6), and a mixture of LT and LT(G33D) (lanes 1 and 2). Each well contained 10 g of protein, and gels were stained with 0.25% Coomassie brilliant blue. Samples in lanes 1, 3, and 5 were unheated. Samples in lanes 2, 4, and 6 were heated to 100°C for 5 min in the presence of dithiothreitol and SDS prior to SDS-PAGE analysis.
ferential binding of SDS to the toxin molecule in unboiled samples.
LT(G33D) was next examined for its ability to bind to GM1, compared with LT and LT-B. As shown in Fig. 2A , in contrast to LT and LT-B, LT(G33D) failed to bind to GM1 on microtiter plates. To exclude the possibility that the mutation in LT(G33D) caused a conformational change in the molecule which would render it unrecognizable by antibody to native LT, we coated plates directly with serial dilutions of LT, LT(G33D), or LT-B. The results shown in Fig. 2B indicate that LT(G33D) is still recognized by antibody against native LT. LT-B is less well recognized by the anti-LT antiserum as expected, due to the absence of the A-subunit epitopes.
Role of receptor binding in toxicity. Next, the effect of LT(G33D) on mouse Y-1 adrenal tumor cells and in the patent mouse model was examined. Since LT has been shown to bind to receptors other than GM1, and since the pathway leading to endosomal uptake is not completely known, it was of interest to determine if LT(G33D) had activity in either the Y-1 adrenal tumor cell assay or the patent mouse model. Reduction in Y-1 adrenal tumor cell activity for a G33D mutant of CT has been established by Jobling and Holmes (28) , but, given the difference in receptors noted above, it was not certain that the effect would be the same for LT(G33D).
The results indicate that in contrast to native LT (titer ϭ 5 pg per well) the activity of LT(G33D) on Y-1 adrenal tumor cells was markedly reduced (titer ϭ 23,435 pg per well), although not completely eliminated (titers were the amounts of toxin required to induce 50% cell rounding; the titer of LT-B was Ͼ100,000 pg per well, the highest amount tested). A logical corollary of these findings is that binding of LT to gangliosides on the membranes of cultured Y-1 adrenal tumor cells is an important but not essential event for induction of morphological changes in these cells, a finding consistent with that reported by Jobling and Holmes (28) for the G33D mutant of CT. One likely explanation for the residual activity of this mutant protein is that LT(G33D) binds to galactose-containing receptors other than GM1 that can serve as functional receptors for internalization of the toxin.
To determine if the receptor-binding mutant was able to activate adenylate cyclase in spite of its inability to bind to the natural receptor, we measured the intracellular levels of cAMP after addition of native LT, LT(G33D), or LT-B to Caco-2 cells. Surprisingly, as shown in Fig. 3 , the cAMP levels induced by LT(G33D) were just slightly lower than those obtained with native LT. Addition of LT(G33D) caused maximal cAMP accumulation (5,000 pmol of cAMP per mg of protein) after 3 h, and native LT caused maximal cAMP accumulation (6,900 pmol of cAMP per mg of protein) at the same time point. This observation suggests that LT(G33D) is being internalized and that the proteolytic processing of the A subunit necessary for adenylate cyclase activation is occurring, despite the inability of LT(G33D) to bind to GM1.
Since LT(G33D) has the ability to activate adenylate cyclase at a level similar to that obtained with native LT but exhibits greatly reduced activity on mouse Y-1 adrenal tumor cells, it was also important to examine whether the mutant exhibits enterotoxicity in vivo. We employed a patent mouse model in which fluid accumulation in the intestine resulting from adenylate cyclase activation can be accurately measured. Three BALB/c mice per group were inoculated intragastrically with various amounts of LT, LT(G33D), or LT-B as indicated in Materials and Methods. As seen in Fig. 4A , native LT in this assay stimulates a dose-dependent increase in fluid accumulation in the gut and, consequently, a dose-dependent increase in the gut/carcass weight ratio. In contrast, even at the highest amount tested (125 g), LT(G33D) did not stimulate fluid accumulation, resulting in a gut/carcass weight ratio similar to that observed for mice receiving the nontoxic LT-B subunit. No enterotoxicity was observed for LT(G33D) in this assay at either 3 (Fig. 4A) or 8 (Fig. 4B) h postinoculation, confirming that binding of the B subunit to GM1 is a requisite for enterotoxicity and the consequent induction of net fluid accumulation in the intestine.
The results of these toxicity assays clearly indicate that the ability of LT to induce morphological changes in cultured Y-1 adrenal tumor cells is markedly decreased in the receptor binding mutant. Moreover, LT(G33D) did not exhibit any toxicity in the patent mouse assay, even after prolonged incubation. However, the levels of cAMP induced by LT(G33D) in Caco-2 cells were not significantly different from those obtained with native LT. These results are seemingly contradictory, but it is possible that Caco-2 cells are able to internalize LT(G33D) following binding to galactosyl-containing receptors other than GM1. It is known that Caco-2 cells display rapid and substantial increases in cAMP levels in response to CT and LT (24, 37) , and it is also possible that the levels of cAMP obtained in cultured cells do not truly reflect the events that occur in vivo.
Role of receptor binding in oral adjuvanticity of LT. As mentioned previously, the report by Nashar et al. (35) makes it clear that the immunogenicity of LT-B is dependent upon efficient receptor binding. However, at this point the role of receptor binding in the oral adjuvanticity of LT was not known. To ascertain the role of receptor binding in oral adjuvanticity, groups of five BALB/c mice were immunized orally with OVA alone or OVA in combination with LT, LT(G33D), or LT-B. Following three weekly oral inoculations all animals were given boosters i.p. with OVA. One week after the i.p. inoculation the animals were sacrificed, and serum and fecal samples were assayed by ELISA for IgG and IgA antibodies directed against OVA and LT.
As shown in Fig. 5 , there was a highly variable serum anti-OVA IgG response in animals orally immunized with OVA in conjunction with either LT(G33D) or LT-B. Animals immunized orally with OVA in conjunction with LT(G33D) exhibited an apparently enhanced serum anti-OVA IgG response compared to animals immunized orally with OVA in conjunction with LT-B or with OVA alone. However, due to the marked variability within groups, these differences were not statistically significant. These responses were significantly lower than the anti-OVA IgG response observed in animals immunized orally with OVA in conjunction with native LT, confirming the ability of native LT to function as an oral adjuvant.
The serum anti-OVA IgA response in mice immunized orally with OVA in conjunction with either LT(G33D) or LT-B could not be distinguished from the response of animals immunized with OVA alone. The serum anti-OVA IgA response in mice immunized orally with OVA in conjunction with native LT was significantly higher than the serum anti-OVA IgA response in mice immunized orally with OVA alone or in conjunction with either LT(G33D) or LT-B. Fecal anti-OVA IgG and IgA responses in all groups were low and fell below the limits of detection for this assay (data not shown). These results clearly indicate that LT must have the intrinsic ability to bind to GM1 in order to have the remarkable adjuvant properties which are characteristic of the native molecule.
Role of receptor binding in immunogenicity of LT. We compared the abilities of LT, LT(G33D), and LT-B to elicit anti-LT IgG and IgA responses in the same animals used for the adjuvanticity studies. As shown in Fig. 6 , after oral administration LT(G33D) induced an anti-LT IgG response that was significantly lower than those induced by LT or LT-B, and it failed to elicit a serum anti-LT IgA response. These observations are consistent with the findings of Nashar et al. (35) but are particularly interesting because in this study the LT holotoxin with an active A subunit was used, while the Nashar et al. (35) study employed the B subunit alone. Fecal anti-LT IgG was not detected in any of the groups (data not shown), while fecal anti-LT IgA responses followed a pattern similar to that observed for serum anti-LT IgA.
To further evaluate the role of receptor binding in the immunogenicity of LT, animals were immunized with LT, LT(G33D), or LT-B parenterally. We reasoned that while GM1 binding might be essential for the mucosal immunogenicity of LT, the overall immunogenicity of the molecule might be different if LT was administered by a parenteral route, bypassing the mucosal surface. For this experiment, three groups of BALB/c mice were immunized i.p. with LT, LT (G33D), or LT-B.
As seen in Fig. 7 , the serum anti-LT IgG response in animals immunized parenterally with LT(G33D) was lower than the response observed in animals immunized with LT-B. Four of the five animals immunized parenterally with an equimolar amount of native LT died within 10 days of inoculation, and the result for the remaining animal is not shown. Taken together, the findings reported in this study make it clear that receptor binding is important for toxicity and immunogenicity and is essential for the oral adjuvanticity of LT.
DISCUSSION
In the present study we examined the role of GM1 binding in the toxicity, immunogenicity, and adjuvanticity of the LT holotoxin. A number of studies have addressed the role of receptor binding in the toxicity of CT or immunogenicity of CT-B and LT-B, but none of the studies reported to date has examined the role of receptor binding in the abilities of these molecules to function as mucosal adjuvants for coadministered antigens. Our results clearly indicate that the ability of LT to act as an oral adjuvant for a coadministered antigen (OVA) is dependent upon its ability to bind to the ganglioside receptor. When OVA was administered orally in conjunction with LT(G33D), the levels of serum anti-OVA IgG or IgA were the same as those obtained when animals were immunized with OVA alone or in conjunction with LT-B.
There are a number of potential cellular targets for these bacterially derived adjuvants, and the precise mechanism of action remains to be determined. Clearly, significant effort has been expended to resolve this question (4, 6, 8, 11, 19-22, 27, 33, 36, 45, 46, 49-51) . Several models have been proposed.
Lycke et al. (33) have proposed that the adjuvanticity of CT and LT is the result of their ability to stimulate hyperabsorption by the luminal enterocytes of the small intestine, an ability which is itself a direct consequence of the ability of these A more recent model for adjuvanticity has been advanced from an evolving understanding of the effects of CT and LT on the induction of oral tolerance (22) . This model proposes that CT and LT abrogate the induction of oral tolerance by depletion of a suppressor T-cell population in the gut-associated lymphoid tissues. Those authors have proposed that adjuvanticity can be explained, in part, by the profound effect of CT on regulatory T cells in the mucosal immune system, specifically by its depletion of the CD8 ϩ intraepithelial lymphocyte population upon oral administration. These investigators concluded that both CT and CT-B (and presumably LT and LT-B) are able to reduce the intraepithelial lymphocyte numbers in vitro and therefore suggested that the inhibitory signal to the T cell is not mediated by the adenylate cyclase pathway nor via the phosphatidylinositol system, both of which require the ADP-ribosylating activity of the holotoxin. Rather, they hypothesized that both CT and CT-B are endocytosed and possibly transcytosed by T cells and that this provides the inhibitory signal required for both oral tolerance and adjuvanticity. It should be noted, however, that neither LT-B nor CT-B has been demonstrated to be an effective oral adjuvant when rendered free of the contaminating A subunit. Recent reports indicate that LT-B and CT-B may have adjuvant activity when administered intranasally, although there is still some disagreement about this point (18, 52) . Studies to investigate the intranasal adjuvanticity of LT(G33D) are under way at this time.
Finally, a role for intestinal epithelial cells in antigen presentation has recently been proposed, insofar as they constitute the vast majority of cells in the small intestine. In contrast, M cells overlying the Peyer's patches constitute only a small percentage of cells in the small bowel. Current theory suggests that it is the M cells which are the predominant antigensampling cells of the gut; these cells then pass internalized antigen to the macrophage cells of the Peyer's patches. These Peyer's patch macrophages serve as the major antigen-presenting cells which initiate T-and B-cell priming in response to oral immunization. However, an alternative pathway of antigen uptake and presentation provided by the absorptive epithelial cells of the intestinal mucosa has been suggested by Bromander et al. (4) . These investigators analyzed the effect of CT exposure on alloantigen presentation by cultured intestinal epithelial cells. The crypt, small intestinal epithelial cell line IEC-17, derived from the duodenum of Sprague-Dawley rats, was cultured with gamma interferon to induce optimal expression of major histocompatibility complex type I and in the presence or absence of CT. After 48 h, the IEC-17 cells were washed, treated with mitomycin, and incubated with histoincompatible spleen cells. Alloantigen-stimulated CD4 ϩ T-cell proliferation was then determined by [ 3 H]thymidine incorporation. CT enhanced the antigen presentation of IEC-17 cells, and this enhancement was due not to an upregulation of major histocompatibility complex type II expression but rather to a dose-dependent increase in interleukin-1 and interleukin-6 secretion by IEC-17 cells. These data suggest that the potent adjuvanticity of CT, and by inference that of LT, may be attributed to its ability to enhance the costimulating ability of antigen-presenting cells such as intestinal epithelial cells. However, it was noted that intestinal epithelial cells have been found to process and present antigens only in vitro and that whether these cells are capable of functioning as antigen-presenting cells in vivo remains to be examined.
Any proposed mechanism of adjuvanticity must account for an increase in levels of serum and mucosal IgA as well as serum IgG directed against the orally administered antigen. We have shown in this study that receptor binding is important for the toxicity and immunogenicity and is essential for the oral adjuvanticity of LT. Whatever mechanism is invoked to explain the events associated with the oral adjuvant properties of these molecules must begin with binding of the B subunit to ganglioside receptors.
